Innovent Biologics (STU:6IB) Debt-to-EBITDA : -2.82 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Innovent Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €156.7 Mil. Innovent Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €308.3 Mil. Innovent Biologics's annualized EBITDA for the quarter that ended in Dec. 2023 was €-165.0 Mil. Innovent Biologics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -2.82.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Innovent Biologics's Debt-to-EBITDA or its related term are showing as below:

STU:6IB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.48 Med: -1.1 Max: -0.14
Current: -5.48

During the past 8 years, the highest Debt-to-EBITDA Ratio of Innovent Biologics was -0.14. The lowest was -5.48. And the median was -1.10.

STU:6IB's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.37 vs STU:6IB: -5.48

Innovent Biologics Debt-to-EBITDA Historical Data

The historical data trend for Innovent Biologics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Debt-to-EBITDA Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.55

-1.71

-1.05

-1.85

-5.48

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial										-0.84	-1.67	-1.76	-94.87	-2.82

Competitive Comparison of Innovent Biologics's Debt-to-EBITDA

For the Biotechnology subindustry, Innovent Biologics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Debt-to-EBITDA falls into.

Innovent Biologics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Innovent Biologics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(156.724	+	308.252)	/	-84.85
	=	-5.48

Innovent Biologics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(156.724	+	308.252)	/	-165.028
	=	-2.82

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Innovent Biologics (STU:6IB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Innovent Biologics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (STU:6IB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (STU:6IB) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 01801:Hong Kong

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (STU:6IB) Headlines

No Headlines